Astra's Covid-19 vaccine sales triple in Q2, top $1 billion in H1

Firm exploring whether vaccine biz is sustainable for next 5-10 years: Official

Second-quarter (Q2) sales of AstraZeneca’s Covid-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on Thursday again delayed its US application for approval as it gathers more data for submissions.

The vaccine has been touted as a major weapon against the pandemic because it is cheaper and easier to use than some rivals. AstraZeneca and its Indian manufacturing partner say they have supplied a billion doses to 170 countries so far. But the shot has also faced setbacks, including disputes over data, production problems, and links to rare side-effects that have led some countries to